BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200403
DTSTAMP:20260515T064617
CREATED:20191104T104106Z
LAST-MODIFIED:20191104T121228Z
UID:23228-1585526400-1585871999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith approvals in a number of indications over the last year\, and more rapidly approaching on the horizon\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies\ndrug developers are employing to improve efficacy\, safety and commercial viability. \nIncorporating insights from 80+ industry-leading speakers\, this conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 600+ of your colleagues to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward in 2020. \nTo know more about 4th Annual Gene Therapy for Rare Disorders click here.
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200402
DTSTAMP:20260515T064617
CREATED:20191215T132020Z
LAST-MODIFIED:20191215T132020Z
UID:23357-1585526400-1585785599@www.pharmajournalist.com
SUMMARY:Cell Engager Summit
DESCRIPTION:The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \n \nUnderstand the very latest in construct design\, immune cell biology\, tumor associated activation\, toxicity assessment\, solid tumor targeting strategies\, clinical insights and more. \nDiscover how to effectively scale complicated manufacturing of multi-specific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies. \nWith 22+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders\, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges. \nTo learn more about this event and to register online\, visit https://ter.li/hkw9b8
URL:https://www.pharmajournalist.com/event/cell-engager-summit-2020/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200401
DTSTAMP:20260515T064617
CREATED:20191215T210012Z
LAST-MODIFIED:20200323T125422Z
UID:23453-1585526400-1585699199@www.pharmajournalist.com
SUMMARY:SMi’s 22nd Annual Superbugs & Superdrugs Conference
DESCRIPTION:A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance \nSponsored by Scynexis \nCO-CHAIRS FOR 2020: Cara Cassino\, Chief Medical Officer\, Contrafect and Michael Dawson\, Director\, Mike Dawson Antimicrobial Research Consultancy \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.superbugssuperdrugs.com \nAs one of the most impactful pharmaceuticals for maintaining public health\, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal\, including colistin\, carbapenems\, 3rd and 4th generation cephalosporins\, useless. \n \nThis year’s event aims to showcase a suite of sessions focused on novel drugs and approaches\, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. \nIt is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR\, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR\, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020\, along with leaders from the pharmaceutical industry\, academia\, regulatory and funding bodies\, and public-private partnerships to discuss the way forward. #SMiBugs \nFEATURED SPEAKERS FOR 2020: \n\nYuri Gleba\, Professor\, Founder\, Nomad Bioscience\nMark Albrecht\, Branch Chief\, Antibacterials program\, BARDA/HHS\nPaul Finn\, CEO\, Oxford Drug Design\nCara Cassino\, Chief Medical Officer\, Contrafect\nMartin Everett\, CSO\, Antabio\nSamareh Lajaunias\, Director\, Combioxin SA\nFrancois Moreau\, Scientific Director\, Mutabilis\nEmma Leire\, Microbiology Lead\, Centauri Therapeutics\nLorenzo Corsini\, Co-Founder/CEO/R&D\, Phagomed\nStephen Barat\, VP\, Preclinical Research and Early Development\, Scynexis\nColm Leonard\, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro \n\nWHATS ON THE AGENDA FOR 2020? \n\nDiscuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience\nGain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin\nExamine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust\nExplore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect\nEvaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design\n\nTo register visit www.superbugssuperdrugs.com/PJWL \nEARLY BIRD-RATES \n\nREGISTER BY 29TH NOVEMBER AND SAVE £400http://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/Holiday Inn Kensington ForumHoliday Inn Kensington Forum\nREGISTER BY 13TH DECEMBER AND SAVE £200\nREGISTER BY 31ST JANUARY AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Rd Kensington\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR